Company Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat.
Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2005 |
| IPO Date | Mar 3, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 184 |
| CEO | Michael A. Metzger M.B.A. |
Contact Details
Address: 35 Gatehouse Drive, Building D, Floor 3 Waltham, Massachusetts 02451 United States | |
| Phone | 781-419-1400 |
| Website | syndax.com |
Stock Details
| Ticker Symbol | SNDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001395937 |
| CUSIP Number | 87164F105 |
| ISIN Number | US87164F1057 |
| Employer ID | 32-0162505 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael A. Metzger M.B.A. | Chief Executive Officer and Director |
| Dr. Neil Gallagher M.D., Ph.D. | President, Head of Research and Development |
| Keith Alan Goldan CPA | Chief Financial Officer, Treasurer and Chief Accounting Officer |
| Luke J. Albrecht | Senior Vice President, General Counsel and Secretary |
| Dr. Catherine Madigan M.D. | Chief Medical Officer |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Richard A. Heyman Ph.D. | Co-Founder |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board |
| Dr. Michael Downes Ph.D. | Co-Founder |
| Sharon Klahre | Vice President of Investor Relations and Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | ARS | Filing |
| Apr 2, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 2, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 18, 2024 | 8-K | Current Report |
| Feb 27, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2024 | 10-K | Annual Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |